Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of t...
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
About this item
Full title
Author / Creator
Martin, Thomas , Krishnan, Amrita , Yong, Kwee , Weisel, Katja , Mehra, Maneesha , Nair, Sandhya , Qi, Keqin , Londhe, Anil , Diels, Joris , Crivera, Concetta , Jackson, Carolyn C. , Olyslager, Yunsi , Vogel, Martin , Schecter, Jordan M. , Banerjee, Arnob , Valluri, Satish , Usmani, Saad Z. , Berdeja, Jesus G. and Jagannath, Sundar
Publisher
Hoboken: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their previous therapy an immunomodulatory drug, proteasome inhibitor, and an anti‐CD38 monoc...
Alternative Titles
Full title
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a405681420e34ef5b0861c5f9532c87e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a405681420e34ef5b0861c5f9532c87e
Other Identifiers
ISSN
2688-6146
E-ISSN
2688-6146
DOI
10.1002/jha2.312
